Curiosity
changes everything.
Relentless pursuit to cure. Original science across antibodies, gene therapies, and regenerative medicine.
See what others
might miss.
Headquartered in North Bethesda, Maryland, Ibex Biosciences, Inc. ("Ibex") distinguishes itself in the early-stage biotech sector with its varied research and development approach.
Ibex is committed to discovering, validating, and developing potential health solutions through investment in unconventional projects and methodologies, irrespective of their recognition within the broader research community.
About IbexScience, in every frame.
A look inside the ideas, environments, and discoveries shaping our work.
Many avenues.
One ambition.
Ibex boasts a diverse portfolio that includes therapeutic antibodies, gene therapies, and regenerative medicine programs.
We are proud of our proven capacity to discover and validate potential therapies from scratch, thus eliminating the need for external technology acquisitions or in-licensing.
Our accomplishments are underscored by a series of in-vivo studies, which have delivered remarkable efficacy against a range of challenging medical conditions.
Therapeutic antibodies
Malaria, oncology, and potential inflammatory applications.
Regenerative platform
Exploring functional repair of damaged cells in situ.
Gene therapies
Research targeting tumors and inflammation.
2024 Future of Malaria Research Symposium
Ibex presents at the 2024 Future of Malaria Research Symposium at John Hopkins
Antibodies targeted to CD147
Ibex announces publication of Antibodies targeted to CD147 (patent pending)
Top Biotechnology Start-up award for 2022
Ibex receives a Top Biotechnology Start-up award for 2022 from Life Sciences Review Magazine.
Antibodies targeted to CD147, including ADC
Watch the original Ibex colon cancer research clip, or the related antibody program video.
Watch related research ↗Explore the opportunity.
Ibex is fundraising under Rule 506(c) of Regulation D. Participation is limited to verified accredited investors. Review the investor materials for details.